Popular GLP-1 drugs — the weight-loss and diabetes medicines that have swept the globe — are linked to nutritional deficiencies in nearly 1 in 6 children who take them, according to a new study.

The finding adds a significant caution to the rapid rise of these drugs among younger patients, where their use has been growing even as long-term data remains limited.

Why deficiencies happen

GLP-1 medicines work in part by suppressing appetite and slowing digestion, which means patients simply eat less. In children and teenagers — who are still growing and have high nutritional needs — eating substantially less can quickly create gaps in vitamins, minerals and protein.

Researchers say the pattern is consistent with what doctors have feared: that dramatic appetite reduction, without careful dietary management, leaves young patients undernourished in ways that may not be immediately visible.

What nearly 1 in 6 means

A deficiency rate approaching one in six is high enough to change clinical practice. It suggests that nutritional monitoring — blood tests, dietitian support and targeted supplementation — should be a standard part of prescribing these drugs to children, not an afterthought.

Paediatric specialists have increasingly called for guardrails around GLP-1 use in minors, arguing that the drugs’ benefits for severe obesity must be weighed against risks to growth and development.

The road ahead

The study is likely to intensify scrutiny of how these medicines are prescribed to young people. Regulators and medical bodies may now face pressure to issue clearer guidance on screening, monitoring and duration of use in children.

For families, the takeaway is not alarm but vigilance: any child on a GLP-1 drug should have their nutrition tracked as carefully as their weight.